{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Mexico Drug Manufacturers - General news", "home_page_url": "https://sharemaestro.com/newsreel/mx/healthcare/drug-manufacturers-general/", "feed_url": "https://sharemaestro.com/newsreel/mx/healthcare/drug-manufacturers-general/feed.json", "description": "Latest Drug Manufacturers - General company headlines from Mexico, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:e142f91199ddc701efe333aa5e8027026f2517e3c090202450a3265d89e820a2", "url": "https://finance.yahoo.com/markets/stocks/articles/bekaert-share-buyback-program-liquidity-061500238.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bekaert-share-buyback-program-liquidity-061500238.html", "title": "Bekaert: Update on the Share Buyback Program and the Liquidity Agreement", "content_text": "Bekaert Update on the Share Buyback Program and the Liquidity Agreement Period from 6 August 2026 to 12 August 2026 Share Buyback Program On 26 February 2026, Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to \u20ac 75 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 6 August 2026 to 12 August 2026, Kepler Cheuvreux SA on behalf of Bekaert has bought 56 000 shares. The table below provides an overview of the transactions under th", "date_published": "2026-08-14T06:15:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "BAYNN"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYNN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/03322f3a-4d3f-49c3-9d58-8d892e092fe9/"}]}}, {"id": "source:628df1dfc51b43eaf5176f665aa8074ea9d077a0712fc5bd8d80d1a4d67c31c5", "url": "https://finance.yahoo.com/markets/stocks/articles/afarak-group-interim-report-h1-060000892.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/afarak-group-interim-report-h1-060000892.html", "title": "AFARAK GROUP: INTERIM REPORT H1 2026", "content_text": "Afarak Group SE 07:00 London, 09:00 Helsinki, 14 August 2026 - Afarak Group SE (\"Afarak\" or \"the Company\") (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2026 H1/26 H1/25 2025 Revenue EUR million 57.1 77.1 141.3 EBITDA EUR million 1.6 6.9 -0.2 EBIT EUR million 0.5 5.9 -2.6 Earnings before taxes EUR million 0.1 3.4 -7.5 (Loss) / Profit for the period EUR million -0.7 2.4 -8.9 Earnings per share EUR 0.00 0.01 -0.03 EBITDA margin 2.8% 9.0% -0.2 EBIT margin 0.8% 7.7% -1.8 Earnings margin 0.2% 4.5% -5.3 Personnel (end of period) 625 613 626 FIRST HALF 2026 HIGHLIGHTS The Group recorded an ", "date_published": "2026-08-14T06:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BAYNN"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYNN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/03322f3a-4d3f-49c3-9d58-8d892e092fe9/"}]}}, {"id": "source:248772e86f849c54af48203e1ed82ca5c5a36ecd4687869763f578f9e29f78bd", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "title": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?", "content_text": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United States, where overall survival was the sole primary endpoint, the trial failed to demonstrate a statistically significant improvement, missing it", "date_published": "2026-08-13T23:38:35+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ABBV"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ff588356-d255-49b7-b368-9d174cfc68c9/"}]}}, {"id": "source:e9910ce59642be6aa999514f06aedcc53452cf2fd331fe433b68b6c9c6898454", "url": "https://finance.yahoo.com/markets/stocks/articles/mlp-se-wbo-mlp-q2-230932085.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/mlp-se-wbo-mlp-q2-230932085.html", "title": "MLP SE (WBO:MLP) (Q2 2026) Earnings Call Highlights: Record Revenue and EBIT Fuel Optimistic Outlook", "content_text": "This article first appeared on GuruFocus. Total Revenue: Increased by 10% to a record EUR583 million in the first half of 2026. EBIT: Reached a new record high of EUR64 million in the first half of 2026. Revenue by Competence Field: Property & Casualty grew 12%, Wealth grew 11%, and Life & Health was slightly above the previous year's levels. Assets Under Management: Increased to a new record level of EUR68.8 billion. Non-life Insurance Premium Volume: Reached a new record high of EUR865 million. Equity: Increased from EUR585 million to EUR589 million compared to the 2025 balance sheet date. R", "date_published": "2026-08-13T23:09:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BAYNN"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYNN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/03322f3a-4d3f-49c3-9d58-8d892e092fe9/"}]}}, {"id": "source:c3a98a5f8747a521982b0d128ec0396d98d710f52be0af746179603a914f830a", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "title": "Johnson & Johnson (JNJ)\u2019s $5.5B Talc Settlement: Turning Point or Temporary Relief?", "content_text": "The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging population is fueling demand for healthcare. US healthcare spending is forecast to hit $6 trillion in 2026 from $5.7 trillion in 2025. This trend reflects an expanding market for medical products companies. Yet for large healthcare companies, legal issues can erode the benefits of favorable mark", "date_published": "2026-08-13T23:07:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e19b7c19-526e-461d-afb3-c5bb3a18f4f2/"}]}}, {"id": "source:fc6f9ec80ab7f72145e43545e812f5b77553f112e9ad3ad2c9cb1395394825e5", "url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "title": "Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth Engine", "content_text": "Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth", "date_published": "2026-08-13T21:46:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1772476d-3e9d-4598-bb50-6351ded7a204/"}]}}, {"id": "source:0cf9b0bafc74581624313018706925e5b7ffbaa1f8371efffb9791a217b0b884", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "title": "Could AbbVie Inc. (ABBV)\u2019s Post-Humira Transformation Drive the Next Phase of Growth?", "content_text": "AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses. Grounded in this solid operational momentum, ABBV raised its full-year 2026 adjusted diluted EPS guidance range to $14.08\u2013$14.28. Adding to its commercial trajectory, AbbVie's Allergan Aesthe", "date_published": "2026-08-13T21:33:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABBV"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ff588356-d255-49b7-b368-9d174cfc68c9/"}]}}, {"id": "source:b86a19034e00afa9d2e6cf46ad3ac437d2c17839da92b496fd0c18240c6c4e29", "url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "external_url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "title": "U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS\u2122, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse", "content_text": "Product Image (Photo: Bristol Myers Squibb)ZENBEXUS\u2122 (iberdomide) Logo Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment class, representing the next chapter in Bristol Myers Squibb's targeted protein degradation platform PRINCETON, N.J., August 13, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has a", "date_published": "2026-08-13T21:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMY"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/122de5b2-fd50-439a-add0-9632363fa758/"}]}}, {"id": "source:06c9383a28c831d166e244315bed34ee2122d4e28940a6a805108264a483d25b", "url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "title": "Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research that highlights Merck's pipeline progress, recent business development moves and continued focus on late stage therapeutics. As you read on, you will see how to track these moving pieces and what they could mean for the evolving Merck story in the coming years. Stay updated as the F", "date_published": "2026-08-13T20:07:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MRK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/2bdb2fd1-4905-4b9c-a83d-617c4c243696/"}]}}, {"id": "source:69a4a7c7fbad651b7d48f5808fc27680e8ea0f4e38147e36a268caab830e0e29", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "title": "Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different patients will want different drugs, delivery methods and trade-offs. For Novo, that is more than a talking point. It is the heart of the comeback story after Lilly's Zepbound grabbed moment", "date_published": "2026-08-13T18:38:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVOBN", "NVON"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVOBN", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/f8af74e2-0372-465c-b306-2b47187ca083/"}, {"symbol": "NVON", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fc6edd35-9731-4914-91d6-4963d8d82068/"}]}}, {"id": "source:b40ec17efd7608a9b538f7a45f663802bba7284e20cc8d0232feee1d3f8ceb2d", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "title": "Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?", "content_text": "Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely driven by the performance of the Wegovy pill, the first oral GLP-1 approved for weight loss, which Novo Nordisk launched in the U.S. in January. The Wegovy pill beat expectations in the first quarter but came up short in the second. What does this mean for the company's prospects?Image source: The Motley ", "date_published": "2026-08-13T17:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOVOBN", "NVON"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVOBN", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/f8af74e2-0372-465c-b306-2b47187ca083/"}, {"symbol": "NVON", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fc6edd35-9731-4914-91d6-4963d8d82068/"}]}}, {"id": "source:ec826990d2c6b2707cb2345a499149ef75cc010896670e707947cc069f7f222f", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "title": "Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk an", "date_published": "2026-08-13T15:12:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOVOBN", "NVON"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVOBN", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/f8af74e2-0372-465c-b306-2b47187ca083/"}, {"symbol": "NVON", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fc6edd35-9731-4914-91d6-4963d8d82068/"}]}}, {"id": "source:f3fab633d584d08932a2870ce562c4f22cbee989985bd7c4a16774be1769ba11", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "title": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation", "content_text": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations. The firm highlighted litifilimab and felzartamab as key assets, with clinical readouts expected over the coming year. Wolfe said litifilimab could become the first biologic approved for cut", "date_published": "2026-08-13T13:52:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "BIIB"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BIIB", "name": "Biogen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/afe83992-07f6-4f9e-a80a-6faafb26e903/"}]}}, {"id": "source:91092dc042f21d2049015aebad19a6bc538732ca2d40d3ea2ae4bb9e13730615", "url": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "external_url": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "title": "MeiraGTx Reports Second Quarter 2026 Financial and Operational Results", "content_text": "MeiraGTx Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition Secured up to $400 million strategic investment from Ob", "date_published": "2026-08-13T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "JNJ"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e19b7c19-526e-461d-afb3-c5bb3a18f4f2/"}]}}, {"id": "source:79ac6a4212879c1730f4d9d7d98c7f0bb6fab689172f414cdbb637101d7d0624", "url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "external_url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "title": "Why Gilead Sciences (GILD) Is Back In The Spotlight", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder retur", "date_published": "2026-08-13T09:11:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "GILD"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1772476d-3e9d-4598-bb50-6351ded7a204/"}]}}, {"id": "source:ca7bd9b0749ebb6a787227418d9a91b874566d623be8c3cd9e785328575d4a6f", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-pfizer-022900266.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-pfizer-022900266.html", "title": "5 Insightful Analyst Questions From Pfizer\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Pfizer's Q2 Earnings Call Pfizer's second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company's performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to \"continued strategic progress\" and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management also pointed to the success of brands like Eliquis and Padcev, noting that commercial teams \"performed with excellence and precision\" across major therapeutic areas. Is now the time to buy PFE? Find out in our full research report (it's free). Pfizer (PFE) Q2 CY2026 Highlights: Revenue: $15.03 billion vs analyst estimates of $14.4 billion (2.6% year-on-year growth, 4.4% beat) Adjusted EPS: $0.77 vs analyst estimates of $0.68 (12.9% beat) The company slightly lifted its revenue guidance for the full year to $61.5 billion at the midpoint from $61 billion Management reiterated its full-year Adjusted EPS guidance of $2.90 at the midpoint Operating Margin: 27.9%, in line with the same quarter last year Organic Revenue rose 1% year on year Market Capitalization: $154.2 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Our Top 5 Analyst Questions From Pfizer's Q2 Earnings Call Evan Seigerman (BMO Capital Markets) asked about the benchmarks for success in the upcoming MEVPRO-1 prostate cancer trial; Chief Scientific Officer Chris Boshoff clarified that a clinically meaningful benefit of 30% over standard care would validate the mechanism. Christopher Schott (JPMorgan) questioned the drivers behind the non-COVID revenue guidance increase and Padcev's growth outlook; Interim CFO Cecile Guegan pointed to broad strength across key brands, with Padcev expected to moderate but remain a major growth engine. Umer Raffat (Evercore ISI) inquired about the commercial potential of mevrometostat; Commercial Chief Aamir Malik emphasized its global opportunity and scale across the disease continuum if approved. Akash Tewari (Jefferies) probed efficacy and future plans for atirmociclib and the impact of proposed changes to 340B hospital payments; Boshoff highlighted atirmociclib's tolerability and planned adjuvant trials, while CEO Bourla noted regulatory uncertainty on reimbursement changes. Terence Flynn (Morgan Stanley) pressed on the sustainability of the dividend amid business development constraints; CEO Bourla asserted that even under stressed scenarios, the dividend would be maintained and could eventually grow post patent expirations. Story Continues Catalysts in Upcoming Quarters In the next several quarters, the StockStory team will be watching (1) clinical readouts for late-stage oncology and obesity programs, (2) the pace of cost savings realization and manufacturing optimization, and (3) the expansion of commercial uptake for recently acquired brands and new product launches. Progress on artificial intelligence integration and further regulatory milestones will also be important indicators of execution. Pfizer currently trades at $26.97, up from $25.03 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it's free for active Edge members). High-Quality Stocks for All Market Conditions ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum \u2014 both boxes checked at the same time. Find out which", "date_published": "2026-08-13T02:29:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "PFE"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a25809d4-86bc-4675-a6db-84b1695cc584/"}]}}, {"id": "source:925017f4be8893e31a12586289c34f0c7ee514ff04b91b00d8b70dac2f840033", "url": "https://finance.yahoo.com/energy/articles/cez-xpra-cez-q2-2026-011013959.html", "external_url": "https://finance.yahoo.com/energy/articles/cez-xpra-cez-q2-2026-011013959.html", "title": "CEZ AS (XPRA:CEZ) (Q2 2026) Earnings Call Highlights: Net Income Rises 10% as Windfall Tax ...", "content_text": "This article first appeared on GuruFocus. Revenue: Operating revenue decreased 5% year-on-year, primarily due to lower power prices. EBITDA: Down 20% to CZK59 billion, impacted by lower generation prices and reduced trading profits. Net Income: Increased 10% to CZK18.1 billion, driven by the absence of the windfall profit tax, which ended on December 31, 2025. Operating Cash Flow: Increased by CZK26 billion, or 55% year-on-year. Capital Expenditures (CapEx): Increased 30% year-on-year. Net Debt: Approximately 9% higher, approaching CZK200 billion. Generation and Mining EBITDA: Decreased by CZK", "date_published": "2026-08-13T01:10:13+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BAYNN"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYNN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/03322f3a-4d3f-49c3-9d58-8d892e092fe9/"}]}}, {"id": "source:75002d510a976d8fb1fd26d66ac0ca94ee02132e471459632ecb609c35c42bda", "url": "https://finance.yahoo.com/technology/ai/articles/gft-technologies-se-wbo-gft-010536877.html", "external_url": "https://finance.yahoo.com/technology/ai/articles/gft-technologies-se-wbo-gft-010536877.html", "title": "GFT Technologies SE (WBO:GFT) (H1 2026) Earnings Call Highlights: AI-Driven Growth and ...", "content_text": "This article first appeared on GuruFocus. Revenue: EUR462.6 million in H1 2026, a 5% increase in both euros and constant currencies. Adjusted EBIT: EUR33 million, up 8% year-over-year, with a margin of 7.1% compared to 6.8% in H1 2025. EBT: EUR24 million, up 26% year-over-year, with the EBT margin improving from 4.3% to 5.2%. Q2 Revenue: EUR233.04 million, a 6% increase versus Q2 2025. Q2 Adjusted EBIT: EUR16.5 million, a 10% increase versus Q2 2025. Order Backlog: Up 18% versus last year. Wynxx Soft Engineering Revenue: EUR24.4 million in actual influenced revenue in H1 2026. Wynxx Business P", "date_published": "2026-08-13T01:05:36+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BAYNN"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYNN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/03322f3a-4d3f-49c3-9d58-8d892e092fe9/"}]}}, {"id": "source:f594c50a2829c0bc45dda3d205dd186eb2ff4b9d76ef9412fb23e929f303f7e5", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-merck-234100386.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-merck-234100386.html", "title": "5 Insightful Analyst Questions From Merck\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic cancers and robust performance in Animal Health as core drivers. CFO Caroline Litchfield highlighted, \"Our strong commercial and operational execution continues to drive near-term performance while we invest in our outstanding pipeline.\" While market reaction was muted, management acknowledg", "date_published": "2026-08-12T23:41:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MRK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/2bdb2fd1-4905-4b9c-a83d-617c4c243696/"}]}}, {"id": "source:c9437f7c9df7d454cc88beb6f60a9bfcb966bbe769c2cf6e3f76f9b179b4936b", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "title": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return ", "date_published": "2026-08-12T21:13:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "JNJ"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e19b7c19-526e-461d-afb3-c5bb3a18f4f2/"}]}}, {"id": "source:5fcdf767edc608cff7fa5cd79c787c8ad280036dafb0cd1562c8c5a696de8af4", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-195841095.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-195841095.html", "title": "Sector Update: Healthcare Stocks Advance Late Afternoon", "content_text": "Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-12T19:58:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MRK"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/2bdb2fd1-4905-4b9c-a83d-617c4c243696/"}]}}, {"id": "source:c8bfa06c7b9fbc27fe482807c5f11f2a9d5007b55d87a343f2383b67a9ff8c80", "url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "title": "Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?", "content_text": "Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio \u2014 including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy \u2014 is becoming central to top-line resilience. Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving revenue durability and supports a more favorable long-term growth outlook. Within this mix, Reblozyl, Breyanzi, Opdualag, Opdivo Qvantig, Camzyos and Cobenfy propelled growth in the first half. Opdivo Qvantig (nivolumab and hyaluronidase-nvhy - subcutaneous formulation) has witnessed strong uptake across all approved tumor types in the United States. Opdivo Qvantig is now generating annualized revenues of more than $1 billion. Other key drugs are contributing to revenue growth, though at varying stages of maturity. Opdualag continues to benefit from robust global demand and its leading position as a standard of care in first-line melanoma in the United States. Reblozyl continues to deliver a stellar performance, driven by solid uptake in first-line MDS-associated anemia, sustained strength in the second-line setting and further penetration among first-line RS-negative patients. Breyanzi's sales continue to be solid, underscoring its strong commercial momentum. Growth is being driven by its best-in-class profile and robust demand across approved large B-cell lymphoma indications in the United States and international markets. The strong performance highlights sustained demand for the therapy and supports expectations for continued commercial expansion. Cardiovascular drug Camzyos continues to deliver solid performance, supported by ongoing promotional efforts, an expanding base of new patient prescribers and deeper penetration into the community setting. In immunology, Sotyktu remains an important growth driver. The recent approval in psoriatic arthritis expands its commercial opportunity and strengthens BMY's presence in rheumatology. Additional upside could come from ongoing phase III programs in systemic lupus erythematosus and Sj\u00f6gren's disease, which may further broaden the drug's addressable market, if successful. Newer products such as Cobenfy for schizophrenia provide additional long-term optionality. Early launch momentum and potential label expansions could establish Cobenfy as another meaningful growth driver over time. Story Continues However, the portfolio transition remains a key challenge. Legacy products, including Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane, still account for 44% of revenues and continue to face significant erosion following the loss of exclusivity for Revlimid, Pomalyst, Sprycel and Abraxane. BMY's Competition in Oncology Space Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. The company competes with big pharma giants like Merck MRK and Pfizer PFE in this space. The immuno-oncology space is dominated by pharma giant MRK's blockbuster drug Keytruda (pembrolizumab). Keytruda is approved for several types of cancer and alone accounts for around 48% of MRK's pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda. Pfizer is one of the largest and most successful drugmakers in the field of oncology. It has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immune-oncology biologics that treat a wide range of cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, including lung cancer. Pfizer's position in oncology was strengthene", "date_published": "2026-08-12T18:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MRK", "PFE", "BMY"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/2bdb2fd1-4905-4b9c-a83d-617c4c243696/"}, {"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a25809d4-86bc-4675-a6db-84b1695cc584/"}, {"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/122de5b2-fd50-439a-add0-9632363fa758/"}]}}, {"id": "source:d9683bb69f74210c4baa0a6b901098dea0f33f985349c2426ac47e1792858586", "url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-expands-adc-181350587.html", "external_url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-expands-adc-181350587.html", "title": "Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses on translational research to speed up biomarker discovery and support precision oncology development. The AI tools are intended to help standardize and accelerate analysis of tumor samples across Gilead's oncology pipeline. Gilead is not the only company leaning into AI to reshape drug discovery and development, so it can be useful to also review stocks tied to the infrastructure that underpins this trend through 57 AI infrastructure stocks.NasdaqGS:GILD Earnings & Revenue Growth as at Aug 2026 Gilead Sciences is a US biopharmaceutical company with a reported market value of about $165.0b, focused on medicines for areas of unmet medical need. Applying Nucleai's AI tools fits with its efforts to better target complex diseases like cancer across large global trials. Beyond the headline: 2 risks and 3 things going right for Gilead Sciences that every investor should see. How does this AI ADC deal fit with what Gilead Sciences is trying to achieve in oncology? The Nucleai partnership fits into Gilead Sciences' effort to build a larger oncology franchise alongside HIV. Using AI tissue analytics across global antibody drug conjugate trials is aimed at tighter biomarker selection and more tailored patient groups, which can support Gilead's efforts to develop newer cancer medicines like Trodelvy. Does this change the Gilead Sciences Narrative for investors? The deal aligns with the existing Narrative that oncology and next generation regimens can diversify Gilead away from heavy HIV dependence. It leans toward the catalyst side of that story, where platforms such as Trodelvy and the Tubulis ADC technology are expected to broaden the portfolio, rather than directly easing policy and pricing risks around HIV. If we take a look at the community Narrative for Gilead Sciences, we can see how this news fits into the bigger investment story. What should investors watch next to see if this AI partnership is working? One potential indicator will be how often Gilead references Nucleai-driven biomarkers or AI-selected patient subgroups in upcoming ADC trial readouts and regulatory filings through 2027. Investors can watch future earnings calls and oncology conference updates for data on response rates or trial timelines that are linked to this AI work. Story Continues For the full picture including more risks and rewards, check out the complete Gilead Sciences analysis. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include GILD. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com", "date_published": "2026-08-12T18:13:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "GILD"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1772476d-3e9d-4598-bb50-6351ded7a204/"}]}}, {"id": "source:fef18f4e280685de7dbc6c50d1d93df3658df1ac06d7c1efcd63083fe71bf0e5", "url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "external_url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "title": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales ", "date_published": "2026-08-12T17:29:11+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "NOVOBN", "NVON", "LLY"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVOBN", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/f8af74e2-0372-465c-b306-2b47187ca083/"}, {"symbol": "NVON", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fc6edd35-9731-4914-91d6-4963d8d82068/"}, {"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/4769ffb6-f12e-498d-bce6-f8bfe5b731e3/"}]}}, {"id": "source:9ea2ad3466fa89ef19f9ade7b95f627db7c366dc80cbdf58a5e5a3b73c6f014e", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-falls-while-172418737.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-falls-while-172418737.html", "title": "Eli Lilly Stock Falls While Retatrutide Lawsuits Expand", "content_text": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase 3 trials. Yet Lilly says compounding pharmacies, medical spas and online vendors are already pushing unauthorized versions for human use, sometimes hiding behind research use only labels. Lilly shares slipped roughly 0.8% Wednesday morning, but this fight is much bigger than one day's stock move. Lilly is defending a drug", "date_published": "2026-08-12T17:24:18+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/4769ffb6-f12e-498d-bce6-f8bfe5b731e3/"}]}}, {"id": "source:2100e637b2916ecb584e6b354b330a6f85d10b7b8fa369baf89de13620dc54c4", "url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "title": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical", "content_text": "Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high and down about 15% over the past twelve months while the S&P 500 returned 22%. A fall that size usually leaves a stock cheap. This one still costs about 37.7 times its last twelve months of adjusted earnings, and what happens to that number by 2027 turns on a price the company has not set. Where The Multiple Actually Lands In 2027 Ana", "date_published": "2026-08-12T17:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "JNJ"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e19b7c19-526e-461d-afb3-c5bb3a18f4f2/"}]}}, {"id": "source:34e5fc56f789693bc2ea43ad70f9c5b8d91a45cd38f0be9635c5e8ee179ac038", "url": "https://finance.yahoo.com/healthcare/articles/absci-absi-early-abs-201-171116760.html", "external_url": "https://finance.yahoo.com/healthcare/articles/absci-absi-early-abs-201-171116760.html", "title": "Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation", "content_text": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci's recent early Phase 1 ABS-201 update and Eli Lilly's US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareh", "date_published": "2026-08-12T17:11:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "LLY"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/4769ffb6-f12e-498d-bce6-f8bfe5b731e3/"}]}}, {"id": "source:28f18b773ccaf69d248383eff739e70477d9fabb13d653ed5d20dbc99c06e7dd", "url": "https://finance.yahoo.com/healthcare/articles/lilly-targets-black-market-retatrutide-165417136.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lilly-targets-black-market-retatrutide-165417136.html", "title": "Lilly Targets Black-Market Retatrutide Sellers", "content_text": "This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY fairly valued? Test your thesis with our free DCF calculator. The company filed six lawsuits against U.S. businesses it accuses of selling unapproved versions of the drug while it remains in clinical development. Retatrutide is still in Phase 3 trials for obesity, type 2 diabetes and related conditi", "date_published": "2026-08-12T16:54:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/4769ffb6-f12e-498d-bce6-f8bfe5b731e3/"}]}}, {"id": "source:dcf747a9ce3991456efb124defaa474880bc72c24deb26b5714a6ef69b7b8a84", "url": "https://finance.yahoo.com/markets/stocks/articles/energy-pharma-giants-quietly-funding-161228567.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/energy-pharma-giants-quietly-funding-161228567.html", "title": "The Energy and Pharma Giants Quietly Funding HDV\u2019s 3% Yield, and How Safe Each One Is", "content_text": "Quick Read XOM and JNJ earn 'Very Safe' dividend ratings inside HDV, backed by interest coverage of 56x and 64 consecutive annual raises. AbbVie's Skyrizi and Rinvoq are replacing Humira faster than expected, but Net Debt/EBITDA of 2.3x keeps a watchlist tag on its dividend. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) The iShares Core High Dividend ETF (NYSEARCA:HDV) leans hard on two sectors to fund its payout. Energy and pharma names account for the top four", "date_published": "2026-08-12T16:12:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "JNJ", "ABBV"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e19b7c19-526e-461d-afb3-c5bb3a18f4f2/"}, {"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ff588356-d255-49b7-b368-9d174cfc68c9/"}]}}, {"id": "source:9073c5771f91b89c5e6ebe007a507f5ff605ec1bb6a0376e88f53fbdfcbb6eb0", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "title": "Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson's focus on higher growth therapeutic and medtech areas that are important for its lo", "date_published": "2026-08-12T16:11:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "JNJ"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e19b7c19-526e-461d-afb3-c5bb3a18f4f2/"}]}}, {"id": "source:89ccdae8021599987b6aa5f490674f932ae2eb912f9372cd9d18a81117ea95ac", "url": "https://finance.yahoo.com/real-estate/articles/nextensa-delivers-strong-half-results-155500459.html", "external_url": "https://finance.yahoo.com/real-estate/articles/nextensa-delivers-strong-half-results-155500459.html", "title": "Nextensa delivers strong half-year results, supported by several successful transactions", "content_text": "Nextensa NV PRESS RELEASE Regulated information Brussels, 12 August 2026, 5:55PM HIGHLIGHTS Nextensadeliversstronghalf-yearresults,supportedbyseveralsuccessful transactions Nextensa achieved strong results in the first half of 2026. The period was marked by several successful transactions, including the sale of Gewerbepark Stadlau in Vienna, the forward sale of The Rock and the sale of B&B Hotels in Cloche d'Or. The granting of the planning and environmental permits for Lake Side in Brussels and the reservation by Vicinity of a substantial residential portion of Bel Towers further underline th", "date_published": "2026-08-12T15:55:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BAYNN"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYNN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/03322f3a-4d3f-49c3-9d58-8d892e092fe9/"}]}}, {"id": "source:50d69488d4ef980edff8dd7a6f29301f4908744fa1aa976b468b34763a9ae28f", "url": "https://finance.yahoo.com/healthcare/articles/bristol-myers-us-2-3-151125664.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bristol-myers-us-2-3-151125664.html", "title": "Is Bristol Myers\u2019 US$2.3 Billion Houston Manufacturing Campus Altering The Investment Case For BMY?", "content_text": "Bristol Myers Squibb recently announced it will invest about US$2.30 billion in a new 600,000-square-foot modular, multi-modal manufacturing campus at Generation Park in Houston, Texas, expected to support production of small molecules, biologics, and antibody-drug conjugates while creating nearly 500 skilled jobs and about 2,000 construction and indirect roles through 2030. This facility's flexible, automation-ready design and alignment with the company's broader US$40.00 billion U.S. investment plan highlight how BMS is building manufacturing capacity that can adjust to its evolving late-stage pipeline and technology needs over decades. Next, we'll examine how this large-scale Houston manufacturing build-out could influence Bristol Myers Squibb's investment narrative and long-term capital allocation. Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution. Bristol-Myers Squibb Investment Narrative Recap To own Bristol Myers Squibb today, you need to believe it can replace earnings from upcoming patent cliffs with a broader, more resilient portfolio while managing pricing and regulatory pressure. The new US$2.30 billion Houston manufacturing campus looks more like a long-term capacity and flexibility move than a needle-mover for near-term earnings or the key short term catalyst, which still centers on how effectively late stage assets and recent launches ramp into meaningful revenue. Among recent announcements, the reported merger discussions with AstraZeneca stand out as most relevant, because any large transaction could materially reshape Bristol Myers Squibb's capital allocation priorities and risk profile. That sits alongside the Houston build out and a long run of R&D alliances as part of a wider effort to address patent expirations, but it also introduces additional uncertainty around integration, balance sheet usage, and how future cash flows might be shared between shareholders and business investment. Yet, against this long term build out story, investors should also be aware that... Read the full narrative on Bristol-Myers Squibb (it's free!) Bristol-Myers Squibb's narrative projects $40.1 billion revenue and $8.6 billion earnings by 2029. This requires a 6.2% yearly revenue decline and an earnings increase of about $1.3 billion from $7.3 billion today. Uncover how Bristol-Myers Squibb's forecasts yield a $62.96 fair value, in line with its current price. Exploring Other Perspectives Story Continues BMY 1-Year Stock Price Chart Some of the most optimistic analysts were already assuming revenues around US$43.3 billion and earnings of about US$10.2 billion by 2029, so if you believe AI enabled R&D and flexible new manufacturing like the Houston site can meaningfully boost productivity, you may see far more upside than the baseline view, while others will focus on the same patent and pricing risks and reach very different conclusions. Explore 8 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth 25% less than the current price! The Verdict Is Yours Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts. A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision. Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance. Ready To Venture Into Other Investment Styles? Opportunities like this don't last. These are today's most promising picks. Check them out now: This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality. Find 49 companies with promising cash flow potential yet trading below their fair valu", "date_published": "2026-08-12T15:11:25+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "BMY"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/122de5b2-fd50-439a-add0-9632363fa758/"}]}}, {"id": "source:de9e2e54cd03494c7c82bc314fdfb47b59256672fe30d3fa8a7dae8f56e46b3e", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "title": "Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?", "content_text": "Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo ", "date_published": "2026-08-12T15:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/4769ffb6-f12e-498d-bce6-f8bfe5b731e3/"}]}}, {"id": "source:3bd1d4ad8bb7d0f063cdf91911b1e774e17c9b40b57c311e89283e66b3dc6fec", "url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "title": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?", "content_text": "Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 2026 results provide particularly strong evidence of this transition. Pfizer's revenues excluding Comirnaty and Paxlovid increased 5% operationally, while its launched and acquired products grew 18% operationally. Pfizer also raised the midpoint of its 2026 revenue guidance by $500 million, with the company attributing roughly $1.5 billion of the improvement to better-than-expected performance of non-COVID products. Established Brands & New Products Drive PFE's Non-COVID Growth A key driving factor behind growth in non-COVID revenues has been the continued rise in sales of several established brands like Vyndaqel and alliance revenues from partner Bristol-Myers BMY for Eliquis. Some internally developed product launches are also contributing to its top-line growth. Key recent product launches include Abrysvo, the first RSV vaccine approved for older adults and for maternal immunization to protect infants; Zavzpret, a nasal spray CGRP antagonist for acute migraine treatment; Hympavzi, a once-weekly treatment for hemophilia A and B with inhibitors; Elrexfio, a BCMA-targeted bispecific antibody for relapsed or refractory multiple myeloma, and Litfulo for severe alopecia areata. PFE's Acquisitions Complement Internal R&D The company is also trying to rebuild its pipeline through acquisitions. Seagen, Metsera and Biohaven are the most significant strategic acquisitions in recent years and could turn out to be transformative opportunities for the company. A key acquired product that has become a significant contributor to revenue growth is Padcev, added from Seagen. In the second quarter, revenues from Pfizer's acquired products like Padcev, Nurtec (added from Biohaven) and others grew 25% operationally, when excluding the impact of certain one-time items in the same quarter a year ago. Pfizer's Pipeline Provides a Second Wave of Growth Pfizer is rebuilding its pipeline in oncology and obesity, which it believes can drive growth in 2028 and beyond. In obesity, Pfizer plans an extensive phase III program for berobenatide, its monthly GLP-1 receptor agonist added from last year's Metsera acquisition, in 2026. Pfizer plans to start more than 20 obesity studies in 2026, including 10 phase III studies for berobenatide for obesity and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea. Pfizer is targeting the first of a series of potential approvals for berobenatide in 2028. However, in the obesity space, Pfizer lags behind leaders like Eli Lilly LLY and Novo Nordisk NVO. Story Continues The currently available and highly popular weight loss GLP therapies, Eli Lilly's Zepbound and Novo Nordisk's Wegovy, are weekly injections. On the other hand, Pfizer's berobenatide starts off as a weekly injection and then switches to a monthly injection. Berobenatide is designed for monthly maintenance dosing. Pfizer is also advancing its oncology clinical pipeline across areas such as breast, thoracic, gastrointestinal and blood cancer. Several oncology candidates have entered late-stage development. Pfizer plans to start four pivotal studies for PF-08634404, a dual PD-1/VEGF inhibitor in-licensed from Chinese biotech 3SBio in 2025. Besides obesity and oncology, Pfizer is advancing candidates in migraine, hemophilia, vaccines, inflammation and immunology. Several of these programs could create additional growth opportunities ove", "date_published": "2026-08-12T15:03:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "PFE", "LLY", "BMY"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a25809d4-86bc-4675-a6db-84b1695cc584/"}, {"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/4769ffb6-f12e-498d-bce6-f8bfe5b731e3/"}, {"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/122de5b2-fd50-439a-add0-9632363fa758/"}]}}, {"id": "source:de3c374c70e34db2b4d2102009d09c2e0ca567a75389b9edbcb742024ff52e00", "url": "https://finance.yahoo.com/markets/stocks/articles/tngx-stock-dips-5-q2-144600756.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/tngx-stock-dips-5-q2-144600756.html", "title": "TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses", "content_text": "Tango Therapeutics TNGX incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents. The company had reported a loss of 35 cents per share in the year-ago quarter. Collaboration revenues were zero compared with $3.2 million a year earlier. Tango shares were down 4.8% on Tuesday, likely due to investor disappointment over the earnings miss. Higher operating expenses weighed on the result. TNGX's Q2 Results in Detail In the absence of a marketed product, Tango has no regular source of income. The company instead reports collaboration revenues periodically, depending on the terms and progress of its collaboration arrangements. All remaining deferred revenues from upfront and research option-extension payments under the Gilead collaboration were recognized during 2025. This followed the truncation of the collaboration agreement, which concluded all research activities. Consequently, Tango recorded no collaboration revenues in the reported quarter. Research and development expenses increased 13% year over year to $37.2 million in the second quarter of 2026. The increase primarily reflected higher spending related to the advancement of the vopimetostat and TNG456 clinical programs. The rise was partly offset by lower spending resulting from Tango's portfolio prioritization efforts. Year to date, TNGX stock has skyrocketed 197.3% compared with the industry's 5.5% growth.Zacks Investment Research Image Source: Zacks Investment Research General and administrative expenses almost doubled year over year to $22.6 million, mainly due to higher personnel-related costs, including share-based compensation. TNGX's Key Pipeline Updates Vopimetostat is Tango's lead pipeline candidate and an MTAP-selective, once-daily PRMT5 inhibitor. In June, the company reported initial data from a phase I/II study evaluating vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant pancreatic cancer. Per the data readout, the combo achieved a 92% objective response rate and 90% six-month progression-free survival rate in this patient population, with a generally well-tolerated safety profile. The findings strengthened Tango's focus on advancing vopimetostat in pancreatic cancer. The company is working internally and has begun discussions with regulators and Revolution Medicines toward developing a registrational plan and path forward for vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer. The design of this impending phase III study of the combo drug in front-line pancreatic cancer is expected to be finalized later in 2026. Story Continues Beyond pancreatic cancer, Tango expects to disclose phase I/II vopimetostat lung cancer monotherapy data later in 2026. The update is expected to provide another clinical readout for the company's lead PRMT5 program in a different tumor setting. The company also plans to release initial data from an early- to mid-stage study of TNG456 for glioblastoma and other cancers and to initiate a phase I/II study of vopimetostat in combination with Erasca's ERAS-0015 in patients with MTAP-deleted RAS-mutant cancers later in 2026, thereby extending development across its broader oncology pipeline. Tango Therapeutics, Inc. Price, Consensus and EPS SurpriseTango Therapeutics, Inc. Price, Consensus and EPS Surprise Tango Therapeutics, Inc. price-consensus-eps-surprise-chart | Tango Therapeutics, Inc. Quote TNGX's Zacks Rank & Stocks to Consider Tango currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Amarin AMRN, Repligen RGEN and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. The estimate for Amarin's 2026 loss per share is currently pegged at 65 cents, while that for 2027 is currently pegged at 51 cents. AMRN shares have gaine", "date_published": "2026-08-12T14:46:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "GILD"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1772476d-3e9d-4598-bb50-6351ded7a204/"}]}}, {"id": "source:f8900e4219a35c506b5d42e453b4b58e174c0fd1ffeb50d0c1dc5612cece6fc9", "url": "https://www.nasdaq.com/articles/1-vanguard-etf-outperforms-sp-500-and-still-has-room-run", "external_url": "https://www.nasdaq.com/articles/1-vanguard-etf-outperforms-sp-500-and-still-has-room-run", "title": "1 Vanguard ETF That Outperforms the S&P 500 and Still Has Room to Run", "content_text": "Key Points The \"Magnificent Seven\" stocks account for over 53% of this Vanguard ETF. This has helped the ETF outperform the S&P 500 in 13 of the past 20 years. Sluggish performance among its top 10 holdings has slowed returns this year.10 stocks we like better than Vanguard Morningstar Growth ETF \u203a The S&P 500 is the stock market's most important index, tracking the 500 largest American companies on the market. It has become the main benchmark investors use to measure their returns, with outperformance and underperformance largely dependent on how it compares. Although investing in an S&P 500 ", "date_published": "2026-08-12T14:35:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Analyst action", "LLY"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/4769ffb6-f12e-498d-bce6-f8bfe5b731e3/"}]}}, {"id": "source:86d62dd42602561cf8e8cd009a104631483eef215b056b5717b74345e252d30d", "url": "https://finance.yahoo.com/m/fccbac36-96b9-3db5-b544-3fb53ab9e0c5/ibd-50-stocks-to-watch%3A.html", "external_url": "https://finance.yahoo.com/m/fccbac36-96b9-3db5-b544-3fb53ab9e0c5/ibd-50-stocks-to-watch%3A.html", "title": "IBD 50 Stocks To Watch: Obesity Drug Giant Eli Lilly Offers New Buy Point", "content_text": "Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens. Continue Reading", "date_published": "2026-08-12T14:29:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLY"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/4769ffb6-f12e-498d-bce6-f8bfe5b731e3/"}]}}, {"id": "source:55dbed5d3c43d81c7484cc84af4c0ea094f5a4393865e303ba587743027088f7", "url": "https://finance.yahoo.com/markets/stocks/articles/pierre-vacances-center-parcs-total-133700984.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/pierre-vacances-center-parcs-total-133700984.html", "title": "Pierre & Vacances-Center Parcs: Total Number of Shares and Voting Rights", "content_text": "Pursuant to Article L. 233-8 of the French Commercial Code and Article 223-16 of the General Regulations of the French Autorit\u00e9 des march\u00e9s financiers PARIS, August 12, 2026--(BUSINESS WIRE)--Regulatory News: Pierre & Vacances-Center Parcs (Paris:VAC): Date Number of shares(*) Number of theoretical voting rights Number of actual voting rights (exercisable at General Meetings) (**) 31 July 2026 462 008 714 462 008 714 461 904 805 (*) Ordinary shares only, i.e. excluding 1,130 preferred shares not admitted to trading. (**) Excluding treasury shares, which are deprived of voting rights (the 1,130", "date_published": "2026-08-12T13:37:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "BAYNN"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYNN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/03322f3a-4d3f-49c3-9d58-8d892e092fe9/"}]}}, {"id": "source:0c4cb6fd7fa515bd38df228d7abe0e62aefbdac0d32cb65b40fdd9eb13fdf3ec", "url": "https://finance.yahoo.com/technology/articles/private-5g-network-deployment-tracker-133400478.html", "external_url": "https://finance.yahoo.com/technology/articles/private-5g-network-deployment-tracker-133400478.html", "title": "Private 5G Network Deployment Tracker & Forecasts 2026-2030 | Covers 9,300 Engagements Across 130 Countries", "content_text": "Company Logo Dublin, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The \"Private 5G Network Deployment Tracker & Forecasts 2026-2030\" has been added to ResearchAndMarkets.com's offering. Private cellular networks remained a specialist segment during the 2G and 3G eras, with deployments such as GSM-R supporting railway communications. The arrival of private LTE in the early 2010s marked a turning point, led by projects including Rio Tinto's mining network in Western Australia, Tampnet's offshore infrastructure and iNET's 700 MHz network in the Permian Basin. Today, private 5G networks are increasingly repla", "date_published": "2026-08-12T13:34:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "BAYNN"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYNN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/03322f3a-4d3f-49c3-9d58-8d892e092fe9/"}]}}, {"id": "source:46b3f23a3cbbf72aa4fa4eff600d629dac6ffd5d600b532526e1abeb25fd4333", "url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "U.K. regulator reaffirms safety of childhood vaccination", "content_text": "[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin", "date_published": "2026-08-12T13:13:40+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Market update", "AZN1N"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AZN1N", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/95985731-f33e-49b3-b4d1-caaa52be687e/"}]}}, {"id": "source:51d09f49a249edf74240a838044ca42e1d3db275594bc2a3bd21270e54e907de", "url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-oppenheimer-now-bullish-125931309.html", "external_url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-oppenheimer-now-bullish-125931309.html", "title": "Intuitive Surgical: Oppenheimer now bullish, sees competition being \"crowded out\"", "content_text": "Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of \"Crowding Out Competitors\" is strategically smart. Analyst Suraj Kalia said the change reflects \"a more nuanced risk-reward assessment at these levels.\" On the positive side, the firm views U.S. competition as a \"non-factor,\" with field checks suggesting \"some unique workflow challenges for Ottava that limit long-term appeal\" and real-estate issues for Hugo. It added that Intuitive's customized price-volume contracts complicate c", "date_published": "2026-08-12T12:59:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "JNJ"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e19b7c19-526e-461d-afb3-c5bb3a18f4f2/"}]}}, {"id": "source:fe4e389d770d2e29836a7265fb0b54c990f811b726528a98df8a2831a7b0d9f0", "url": "https://finance.yahoo.com/healthcare/articles/why-revolution-medicines-may-big-125024116.html", "external_url": "https://finance.yahoo.com/healthcare/articles/why-revolution-medicines-may-big-125024116.html", "title": "Why Revolution Medicines May Be Big Pharma\u2019s Next Takeover Target", "content_text": "Quick Read RVMD has surged 492% over one year on daraxonrasib's landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival. MRK ranks as the most likely acquirer, with Keytruda's patent cliff mounting pressure and CEO Robert Davis pledging to diversify its growth portfolio. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Revolution Medicines (NASDAQ:RVMD) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform ", "date_published": "2026-08-12T12:50:24+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "JNJ"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e19b7c19-526e-461d-afb3-c5bb3a18f4f2/"}]}}, {"id": "source:93a8437a003e42bdc1cec61e325e382b08164d5e79e56bcc2ecbd8cc4c72cb21", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "title": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall", "content_text": "This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulator", "date_published": "2026-08-12T12:25:19+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "JNJ"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e19b7c19-526e-461d-afb3-c5bb3a18f4f2/"}]}}, {"id": "source:7f86b5227bc22a9752a278a909c94b778e142bfa5917ec7e264a507df28aa63b", "url": "https://finance.yahoo.com/healthcare/articles/madrigal-appoints-john-c-reed-120000934.html", "external_url": "https://finance.yahoo.com/healthcare/articles/madrigal-appoints-john-c-reed-120000934.html", "title": "Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors", "content_text": "Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson (\"J&J\") and is a member of J&J's Executive Committee, where he leads research and development across oncology, immunology, neuroscie", "date_published": "2026-08-12T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "JNJ"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e19b7c19-526e-461d-afb3-c5bb3a18f4f2/"}]}}, {"id": "source:e36d474eb97ad2c336075d3dfe5a331dd95140d361056163840fbc0c12cb09bc", "url": "https://finance.yahoo.com/markets/stocks/articles/changes-full-guidance-biomar-113300186.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/changes-full-guidance-biomar-113300186.html", "title": "Changes to full-year guidance for BioMar", "content_text": "Aktieselskabet Schouw & Co. Today, BioMar has released an announcement with updated guidance for the full year 2026. BioMar now expects revenue in the range of DKK 17-18 billion against previously DKK 16-17 billion and EBIT in the range of DKK 1,200-1,300 million compared to previously DKK 1,100-1,200 million. BioMar constitutes a material part of the portfolio and is fully consolidated into the Schouw & Co. figures, and the information from BioMar will be incorporated into Schouw & Co.'s guidance. Schouw & Co. provides guidance to the market on revenue and EBITDA and will consider its consoli", "date_published": "2026-08-12T11:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "BAYNN"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYNN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/03322f3a-4d3f-49c3-9d58-8d892e092fe9/"}]}}, {"id": "source:42172907b7c3be71dbc848985f4a5239d8f2f8916ed25fc4e50f87f9eb8e2147", "url": "https://finance.yahoo.com/healthcare/articles/arbutus-reports-second-quarter-2026-113000778.html", "external_url": "https://finance.yahoo.com/healthcare/articles/arbutus-reports-second-quarter-2026-113000778.html", "title": "Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update", "content_text": "Arbutus Biopharma Corporation Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus shareholders Filed three international patent enforcement lawsuits against Pfizer and BioNTech related to lipid nanoparticle (LNP) technology Achieved alignment with the U.S. Food and Drug Administration (FDA) on a proposed imdusiran Phase 2b clinical trial design WARMINSTER, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (\"Arbutus\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on infectious disease, today reported second quarter 2026 financial results and provided a corporate update. LNP Litigation On March 3, 2026, Arbutus, along with its exclusive licensee, Genevant Sciences (\"Genevant\"), entered into a settlement agreement to resolve all global patent infringement litigation and patent revocation proceedings involving Moderna. As part of the settlement, Moderna paid Arbutus and Genevant $950 million in July 2026 (the \"Noncontingent Settlement Payment\") and will pay an additional $1.3 billion contingent upon an appellate ruling that 28 U.S.C. \u00a71498 does not bar Arbutus' and Genevant's claims against Moderna for patent infringement, except as to doses characterized by the district court as having gone to U.S. government employees. On July 8, 2026, the Company received $178.4 million as its share of the Noncontingent Settlement Payment, which includes reimbursement of the Company's litigation costs. In addition, the Company owns approximately 16% of the outstanding common equity of Genevant and anticipates the payment of a material dividend from Genevant in the third quarter of 2026. For more information about the terms and conditions of the settlement with Moderna, including the contingent payment, please refer to Arbutus' Quarterly Report on Form 10-Q to be filed with the SEC on August 12, 2026 and Annual Report on Form 10-K filed with the SEC on March 23, 2026. In July 2026, the Company, along with Genevant, filed three international lawsuits against Pfizer, BioNTech and certain of their affiliates seeking to enforce patents protecting the Company's patented LNP technology across 21 countries. Corporate Updates Arbutus expects to return capital to shareholders commencing in Q3 2026 through repurchases of up to approximately $230 million of the Company's common shares, which repurchases may come in the form of a tender offer (including a modified \"Dutch Auction\" tender offer), open market purchases, accelerated share repurchases or other means. The specific form(s) of any such transaction(s) remains subject to the approval of the Company's board of directors, and no assurance can be given that any such repurchase activity will occur in Q3 2026, or at all. In April 2026, the FDA granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B (\"cHBV\"). The FDA's Fast Track program is designed to facilitate the development and expedite the review of investigational therapies to treat serious conditions with unmet medical need. In May 2026, the Company reached alignment with the FDA on the design and safety parameters of a proposed Phase 2b clinical trial evaluating imdusiran for the treatment of cHBV. The Company intends to incorporate the FDA's feedback into a final Phase 2b protocol. Story Continues \"This has been an exciting quarter for our imdusiran development program,\" said Lindsay Androski, President and CEO of Arbutus. \"In addition to obtaining Fast Track designation from the FDA on this promising drug candidate, which has achieved functional cure in 10 chronic hepatitis B patients to date, we reached alignment with the FDA on the design of our Phase 2b clinical trial. I would like to publicly congratulate our research and development team for ", "date_published": "2026-08-12T11:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "PFE"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a25809d4-86bc-4675-a6db-84b1695cc584/"}]}}, {"id": "source:a98bf40dc28964028c314674c98bb3ba67f672de930dcedcae5839f480c10811", "url": "https://finance.yahoo.com/healthcare/articles/indupro-closes-77-million-series-113000456.html", "external_url": "https://finance.yahoo.com/healthcare/articles/indupro-closes-77-million-series-113000456.html", "title": "InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001", "content_text": "IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company SEATTLE & CAMBRIDGE, Mass., August 12, 2026--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane pro", "date_published": "2026-08-12T11:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLY"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/4769ffb6-f12e-498d-bce6-f8bfe5b731e3/"}]}}, {"id": "source:bf7defe4a71158af0a1bd84bf51ac804a6c1a409a21dd1ca573562c764d9813c", "url": "https://seekingalpha.com/news/4631300-lilly-files-six-lawsuits-to-crack-down-on-black-market-retatrutide-weight-loss-shots?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631300-lilly-files-six-lawsuits-to-crack-down-on-black-market-retatrutide-weight-loss-shots?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Lilly files six lawsuits to crack down on black market retatrutide weight-loss shots", "content_text": "[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Lilly escalated its fight against black-market retatrutide by filing six new lawsuits against U.S. sellers, including compounding pharmacies, medical spas, and online vendors, the drugmaker said Wednesday in a statement [https://seekingalpha.com/pr/20616057-lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal]. The company said retatrutide remains an investigational Phase 3 molecule, and no retatrutide medicine has been approved for human use by any regulator worldwide. The FDA has made c", "date_published": "2026-08-12T09:41:38+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/4769ffb6-f12e-498d-bce6-f8bfe5b731e3/"}]}}, {"id": "source:598e9075e70015a8ed86ba0f87e4ec63ce23413315cab77717ad26d7d1f31fd6", "url": "https://finance.yahoo.com/healthcare/articles/lilly-calls-online-platforms-payment-093000432.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lilly-calls-online-platforms-payment-093000432.html", "title": "Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market", "content_text": "Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business\u2014social media and e-commerce platforms, credit card companies, payment processors an", "date_published": "2026-08-12T09:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/4769ffb6-f12e-498d-bce6-f8bfe5b731e3/"}]}}, {"id": "source:ee2012b426ba5b32f8f9770cbf19ac68a207ef1594a8b2065c3c2e011868767c", "url": "https://www.nasdaq.com/articles/if-i-were-my-40s-id-buy-vanguard-etf-warren-buffett-recommended-and-hold-it-forever", "external_url": "https://www.nasdaq.com/articles/if-i-were-my-40s-id-buy-vanguard-etf-warren-buffett-recommended-and-hold-it-forever", "title": "If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever", "content_text": "Key Points Warren Buffett steered the Berkshire Hathaway holding company to market-crushing returns for 60 years. He often said everyday investors could do well by simply buying an exchange-traded fund that tracks a diversified index like the S&P 500. In February 2014, he specifically recommended the Vanguard S&P 500 ETF because of its ultra-low fees, and it could help investors achieve a secure retirement. 10 stocks we like better than Vanguard S&P 500 ETF \u203a Warren Buffett served as chief executive officer of the Berkshire Hathaway(NYSE: BRKA)(NYSE: BRKB) holding company between 1965 and 2025", "date_published": "2026-08-12T09:17:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "LLY", "JNJ", "ABBV"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/4769ffb6-f12e-498d-bce6-f8bfe5b731e3/"}, {"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e19b7c19-526e-461d-afb3-c5bb3a18f4f2/"}, {"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ff588356-d255-49b7-b368-9d174cfc68c9/"}]}}]}